Anastrozole vs Tamoxifen in DCIS

Video
Conference|American Society of Clinical Oncology Annual Meeting (ASCO)

In this video we discuss the results of the NSABP B-35 trial of anastrozole vs tamoxifen in postmenopausal women with DCIS who had undergone lumpectomy plus radiation therapy.

In this video Richard G. Margolese, MD, of McGill University in Montreal, discusses the results of the NSABP B-35 trial of anastrozole vs tamoxifen in postmenopausal women with DCIS who had undergone lumpectomy plus radiation therapy.

Dr. Margolese presented results of the study at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ASCO Annual Meeting, from hot topics and emerging trends to travel recommendations.
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
Beta emitters like 177Lu-rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer.
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
Clinical trials conducted in recent years demonstrate the benefit of integrative oncology for patients undergoing treatment for cancer.
Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.
Future work may focus on optimizing symptom management associated with percutaneous transesophageal gastrostomy placement in malignant bowel obstructions.
Related Content
AI Transforms HER2-Low, HER2-Ultralow Breast Cancer Diagnostics for Pathologists

AI Transforms HER2-Low, HER2-Ultralow Breast Cancer Diagnostics for Pathologists

Sabrina Serani
May 23rd 2025
Article

AI-assisted training dramatically reduced HER2-null overscoring and improved sensitivity in HER2-low and HER2-ultralow breast cancer cases.

Key CAR T and Transplantation Presentations From The 2025 Tandem Meeting

Key CAR T and Transplantation Presentations From The 2025 Tandem Meeting

Rahul Banerjee, MD, FACP;Shernan Holtan, MD
March 3rd 2025
Podcast

Shernan Holtan, MD, and Rahul Banerjee, MD, FACP, discussed various trials of significance shared as posters and presentations at the 2025 Tandem Meeting.

Final OS data from INAVO120 demonstrate, for the first time, a significant OS improvement with a PI3K-targeted agent in this breast cancer population.

Inavolisib Combo Significantly Extends Survival in PIK3CA+ Breast Cancer

Caroline Seymour
May 22nd 2025
Article

Final OS data from INAVO120 demonstrate, for the first time, a significant OS improvement with a PI3K-targeted agent in this breast cancer population.

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

Paolo Tarantino, MD;Matteo Lambertini, MD
January 13th 2025
Podcast

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

65 The Outcomes of Nipple Sparing Goldilocks Mastectomy in a Primarily Overweight and Obese Population

65 The Outcomes of Nipple Sparing Goldilocks Mastectomy in a Primarily Overweight and Obese Population

Allen Gee;Grace Oh;June Lee
May 12th 2025
Article
67 Confocal Laser Scanning Microscopy (CLSM) for Intraoperative Histopathological Margin Assessment in Breast Conservation Surgery

67 Confocal Laser Scanning Microscopy (CLSM) for Intraoperative Histopathological Margin Assessment in Breast Conservation Surgery

Ken Weixing Ho;Nicholas Holford;Rathi Ramakrishnan;Patriek Jurrius;Sarah Pinder;Arnie Purushotham;Daniel Leff
May 11th 2025
Article